Trial Profile

Natalizumab Treatment of Progressive Multiple Sclerosis [Natalizumabbehandling af progressiv multipel sklerose]

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Natalizumab (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms NAPMS

Most Recent Events

28 Oct 2022 Results from NCT01144117, NCT01077466 and other study ; comparing effects on lesion activity, brain atrophy and microstructure of lesions, normal-appearing white matter (NAWM) and cortical grey matter (CGM) in progressive MS, presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
28 Mar 2014 Primary endpoint 'Osteopontin-levels' has been met.
28 Mar 2014 Results published in the Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com